Wiley Blackwell

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Motzer
    Motzer
  3. Brennan
    Brennan
  4. Shah
    Shah
  5. Danishefsky
    Danishefsky
  6. Vickers
    Vickers
  7. Russo
    Russo
  8. Shaha
    Shaha
  9. Eastham
    Eastham
  10. Scardino
    Scardino

Groups

  1. Department of Medicine (1537)
  2. Surgery (1247)
  3. Solid Tumor Oncology Division (893)
  4. Survivorship Research (827)
  5. GSK Faculty (671)
  6. Population Sciences Research Program (628)
  7. Sloan Kettering Institute Faculty (612)
  8. Department of Pathology and Laboratory Medicine (555)
  9. Epidemiology and Biostatistics (494)
  10. Center for Hematologic Malignancies (437)
Search Within
Formats
  1. Journal Article (3530)
  2. Meeting Abstract (684)
  3. Review (200)
  4. Book Section (107)
  5. Conference Paper (94)
  6. Editorial (91)
  7. Research Letter (35)
  8. Guidelines (28)
  9. Correspondence (25)
  10. Miscellaneous (5)
  11. Book Whole (3)
Groups
  1. Department of Medicine (1537)
  2. Surgery (1247)
  3. Solid Tumor Oncology Division (893)
  4. Survivorship Research (827)
  5. GSK Faculty (671)
  6. Population Sciences Research Program (628)

More Groups

People
  1. Harry Herr (92)
  2. Robert Motzer (87)
  3. Murray Brennan (86)
  4. Jatin Shah (77)
  5. Andrew Vickers (74)
  6. Samuel Danishefsky (74)

More People

Years
  1. 2025 (147)
  2. 2024 (192)
  3. 2023 (261)
  4. 2022 (186)
  5. 2021 (221)
  6. 2020 (183)

More Years

Publications
  1. Cancer (1461)
  2. Journal of Surgical Oncology (376)
  3. BJU International (338)
  4. Hematological Oncology (199)
  5. Histopathology (158)
  6. EMBO Journal (132)

More Publications

Results (4802)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First‐in‐human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS‐3201b) in patients with relapsed or refractory non‐Hodgkin lymphomas
    Meeting Abstract

    Ishitsuka, K.; Izutsu, K.; Maruyama, D.; Makita, S.; Jacobsen, E. D.; Horwitz, S.; Kusumoto, S.; Allen, P.; Porcu, P.; Imaizumi, Y.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Characteristics of patients achieving complete or partial response (CR/PR) with tazemetostat (TAZ) in wild‐type relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Salles, G.; Tilly, H.; Chaidos, A.; McKay, P.; Phillips, T.; Assouline, S.; Campbell, P.; Ribrag, V.; Laurent Damaj, G.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Prognostic significance of time from last therapy in patients with diffuse large B‐cell lymphoma: Retrospective analysis of electronic health records and claims data in the US
    Meeting Abstract

    Matasar, M.; Castro, F.; Liu, Y.; Abraham, A.; Oki, Y.; Dickinson, M.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Time to second line Bruton tyrosine kinase therapy and age at its initiation are strongly associated with subsequent overall survival in patients with first relapse of mantle cell lymphoma
    Meeting Abstract

    Villa, D.; Jiang, A.; Crosbie, N.; Rule, S.; McCulloch, R.; Visco, C.; Buege, M. J.; Kumar, A.; Bond, D.; Paludo, J.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Zandelisib, a PI3Kδ inhibitor on intermittent schedule (IS) in follicular lymphoma patients who progressed within 24 months of first‐line chemoimunotherapy (POD24)
    Meeting Abstract

    Pagel, J.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H.; Kenkre, V. P.; Soumerai, J. D.; Llorin‐Sangalang, J.; Gorbatchevsky, I.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Patients with out of specification tisagenlecleucel can be salvaged with a point‐of‐care car T‐cells: An observational intention‐to‐treat single‐center analysis
    Meeting Abstract

    Fried, S.; Shouval, R.; Varda‐Bloom, N.; Besser, M.; Yerushalmi, R.; Shem‐Tov, N.; Danylesko, I.; Jacoby, E.; Teihman, S.; Shimoni, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO‐305), a next generation highly selective non‐covalent BTK inhibitor in previously treated richter transformation: Results from the phase 1/2 bruin study
    Meeting Abstract

    Jurczak, W.; Shah, N. N.; Lamanna, N.; Eyre, T. A.; Woyach, J.; Lech‐Maranda, E.; Wierda, W. G.; Lewis, D.; Thompson, M. C.; Wang, D.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save